Clinical Trial Update: Phase I Clinical Trial of ManNAc in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM) [Phase 1]

View source ↗

Summary

Phase I trial of ManNAc (N-acetylmannosamine) in patients with GNE myopathy and hereditary inclusion body myopathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gne Myopathy
• Hereditary Inclusion Body Myopathy

Drugs mentioned

• ManNAc (N-acetylmannosamine)

Snippet

Sponsor: National Human Genome Research Institute (NHGRI) | Conditions: Hereditary Inclusion Body Myopathy (HIBM), GNE Myopathy | Phase 1 | Status: COMPLETED